(VIANEWS) – Shares of BIOSENIC (BEL 20: BIOS.BR) rose by a staggering 10.08% to €0.14 at 10:09 EST on Monday, following the last session’s downward trend. BEL 20 is dropping 1.76% to €3,539.30, following the last session’s downward trend. This seems, so far, an all-around negative trend trading session today.
About BIOSENIC
BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures. The company is based in Mont-Saint-Guibert, Belgium.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BIOSENIC’s stock is considered to be overbought (>=80).
More news about BIOSENIC (BIOS.BR).
